ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.

Zhejiang Tianyu Pharmaceutical Co., Ltd.

300702

CNE1000034X1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
20.49 ^CNY	-0.97%		-2.98%	-5.62%

May. 06	China Approves Tianyu Pharma's Heart Medication	MT
Apr. 26	Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2023	CI

Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.4 billion in funding

June 15, 2023

Zhejiang Tianyu Pharmaceutical Co., Ltd. announced a private placement of convertible bonds for gross proceeds of up to CNY 1,400 million on June 16, 2023.

Latest news about Zhejiang Tianyu Pharmaceutical Co., Ltd.

China Approves Tianyu Pharma's Heart Medication	May. 06	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2023	Apr. 26	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 24, 2024.	Apr. 02	CI
Zhaoxin Liaowang No. 1 Private Securities Investment Fund managed by Jiangsu Zhaoxin Private Fund Management Co., Ltd. entered into a share transfer agreement to acquire 6.19% stake in Zhejiang Tianyu Pharmaceutical Co., Ltd. from Ganzhou Zhenhan Venture Capital Co., Ltd. for CNY 310 million.	Mar. 19	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	Jan. 24	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	Jan. 23	CI
Tianyu Pharmaceutical Unit Passes US FDA's On-Site Inspection	Nov. 22	MT
Tianyu Pharma Unit Passes US FDA On-Site Inspection	Nov. 20	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Zhuhai Rundu Pharma Gets Supplementary Application Approval For Hypertension Drug	23-07-26	MT
Raw Drug Material of Tianyu Pharma's Unit Passes Regulatory Evaluation	23-06-16	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.4 billion in funding	23-06-15	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Management Changes	23-05-23	CI
Tianyu Pharmaceutical Unit Gets Approval to Market Hypertension Drug in China	23-05-09	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Zhejiang Tianyu Pharma Unit Gets Marketing Approval For Losartan Potassium Tablets	23-02-20	MT
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022.	22-12-15	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 30, 2022, has expired with 2,403,643 shares, representing 0.69% for CNY 58 million.	22-12-14	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.(SZSE:300702) dropped from Shenzhen Stock Exchange Component A Share Index	22-12-09	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.(SZSE:300702) dropped from Shenzhen Stock Exchange Component Index	22-12-09	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022.	22-10-11	CI

Chart Zhejiang Tianyu Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Tianyu Pharmaceutical Co., Ltd.

More charts

Zhejiang Tianyu Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of chemical raw materials. The Company operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The Company also operates Other segment. The Company sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Tianyu Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.49 CNY

Average target price

22.6 CNY

Spread / Average Target

+10.30%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.	-5.62%	986M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.59%	44.15B
OTSUKA HOLDINGS CO., LTD.	+23.03%	23.02B
SANDOZ GROUP AG	+18.22%	15.33B
CIPLA LIMITED	+12.26%	13.74B
ZYDUS LIFESCIENCES LIMITED	+52.55%	12.16B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.66B

Generic Pharmaceuticals